While nanobodies offer a host of advantages, their widespread adoption is still limited by the challenges of manufacturing and production scalability. The traditional method for producing nanobodies involves immunizing camelids, which can be a complex and expensive process. Furthermore, the purification and large-scale production of these products can be a major hurdle for many companies. The market is therefore seeing a greater focus on developing more efficient and cost-effective methods for producing nanobodies, such as through the use of microbial expression systems like E. coli and yeast. The Nanobody Market report implicitly recognizes this by focusing on a market that is driven by a need for improved patient outcomes but also faces significant ethical and regulatory challenges.

The future of the Nanobody Market will be defined by the ability of companies to not only provide high-quality products but also to build a strong and sustainable manufacturing infrastructure. This will be essential for gaining a competitive advantage in a market that is increasingly dependent on technology.